Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 100 participants.

Also called NCT01267448

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01267448
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01267448. Randomized; no masking; primary purpose treatment. Start 2014-09-09 (actual); primary completion 2015-07-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
Condition
Diabetes Mellitus Type 2
Condition
Hyperglycemia
Intervention (Drug)
Glipizide XL
Intervention (Drug)
Saxagliptin + Metformin XR
Intervention (Drug)
Metformin XR
Lead sponsor
Cook County Health (class: other government)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01267448
Content hash
9342ff6ed8679f29a38e6eb8d46cdfbdb1c573e93313775cb9679f482afbde8e